(Q71763094)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6861845%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

title

Endralazine, a new peripheral vasodilator. Evaluation of safety and efficacy over a 3 year period (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6861845%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

author name string

W A Bogers

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6861845%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

L Meems

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6861845%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

publication date

1 January 1983

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6861845%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Clinical Pharmacology

21 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6861845%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6861845%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

page(s)

301-305

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6861845%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6861845%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf00610045

21 October 2019

exact match

0 references

cites work

Sensitive high-performance liquid chromatographic assay for endralazine and two of its metabolites in human plasma

1 reference

12 December 2020

Hemodynamic study on a new antihypertensive drug (a pyridopyridazine) in the treatment of hypertensive crisis and resistent hypertension. First findings in man (author's transl)

1 reference

12 December 2020

Problems with Practolol

1 reference

12 December 2020

Immunological studies of collagens modified by reaction with hydralazine

1 reference

12 December 2020

Clinical effectiveness of BQ 22-708, a pyridopyridazine derivative, in the treatment of fixed essential hypertension

1 reference

12 December 2020

Treatment of hypertension with a combination of pyridopyridazine derivative with a beta-receptor blocker. Studies on the hemodynamic course (author's transl)

1 reference

12 December 2020

Induction of antibodies to nuclear antigens in rabbits by immunization with hydralazine-human serum albumin conjugates

1 reference

12 December 2020

Minoxidil in resistant hypertension

1 reference

12 December 2020

Acetylator phenotype and lupus erythematosus

1 reference

12 December 2020

Hydrallazine-induced lupus erythematosus-like syndrome in a patient of the rapid acetylator phenotype

1 reference

12 December 2020

Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis

1 reference

12 December 2020

[Management of treatment-resistant hypertension: comparison of the antihypertensive effect of endralazine and minoxidil (author's transl)]

1 reference

12 December 2020

Pharmacologic effects of the antihypertensive 6-benzoyl-3-hydrazino-5,6,7,8-tetrahydropyrido[4,3-c]pyridazine (BQ 22-708, endralazine)

1 reference

12 December 2020

Hydrallazine in hypertension: is there a safe dose?

1 reference

12 December 2020

Further evidence for an acetylator phenotype difference in the metabolism of hydralazine in man.

1 reference

12 December 2020

Effect of dose on acetylator phenotype distribution of hydralazine

1 reference

12 December 2020

Simplified method for determining acetylator phenotype.

1 reference

12 December 2020

Acetylator phenotype in patients with hydralazine-induced lupoid syndrome.

1 reference

12 December 2020

Kinetics of hydralazine and its main metabolites in slow and fast acetylators

1 reference

12 December 2020

Hydralazine-pyrimidine interactions may explain hydralazine-induced lupus erythematosus

1 reference

12 December 2020

Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome

1 reference

12 December 2020

Antinuclear Antibodies and Cardiovascular Drugs

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00610045

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6861845%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

1 reference